GlassScriptPhysician profile
Luis C Ortiz
NPI 1649230442
$2,566.04
in general payments reported to CMS, 2019-2025
15 companies · $242 in 2025
The $242 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $604 · 2020: $211 · 2021: $211 · 2022: $345 · 2023: $341 · 2024: $612 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,194.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,339.57 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $242.19 | 2019-2024 | Jardiance |
| Pbg Puerto Rico LLC | $241.18 | 2019-2022 | |
| Pfizer INC. | $137.40 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.61 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Xeris Pharmaceuticals, INC. | $113.45 | 2024 | Recorlev |
| Abbvie INC. | $67.22 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $63.54 | 2020-2021 | |
| Revance Therapeutics, INC. | $63.12 | 2024 | Daxxify |
| Merck Sharp & Dohme LLC | $60.55 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $25.00 | 2023 | Eliquis |
| Bayer Puerto Rico INC. | $22.45 | 2025 | Kerendia |
| Sanofi-Aventis U.S. LLC | $20.73 | 2019 | |
| Boston Scientific Corporation | $20.33 | 2025 | Watchman Flx |
| Pfizer Pharmaceuticals LLC | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.